Prostate Cancer Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Others), By Drug Class (Androgen Receptor Inhibitors, Microtubule Inhibitors, Gonadotropin-Releasing Hormone Agonist, Gonadotropin-Releasing Hormone Receptor Antagonist, and Others), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies) and Region Forecast 2020-2031

Prostate Cancer Therapeutics Market size was valued at US$ 11,181.2 million in 2024 and is projected to reach US$ 20,049.1million by 2031 at a CAGR of 8.7% from 2025-2031. Moreover, the U.S. Prostate Cancer Therapeutics Market is projected to grow significantly, reaching an estimated value of US$ 6,255.3 Million by 2031. Prostate cancer is a type of cancer that occurs in the prostate, a small, walnut-shaped gland in men that produces seminal fluid, which nourishes and transports sperm. It typically grows slowly and may initially remain confined to the prostate gland, and sometimes may cause serious harm.

The market is witnessing substantial growth, primarily driven by the increasing prevalence of prostate cancer, especially among aging male populations. Improved awareness, early screening programs, and advances in diagnostic tools such as PSA testing are prompting early detection and timely treatment, fostering demand for advanced therapies like androgen deprivation therapy and targeted drugs. A key trend shaping the market is the shift toward precision medicine, where genomic profiling enables the use of personalized treatments such as PARP inhibitors and immunotherapies, improving outcomes while reducing side effects. Artificial intelligence and companion diagnostics are also enhancing early diagnosis and therapy alignment.

An emerging opportunity lies in the development of next-generation androgen receptor inhibitors and radioligand therapies, alongside the growth of digital health tools that facilitate remote monitoring. These innovations are especially impactful in expanding access in underserved regions. However, the market faces restraints such as the high cost of novel therapies, limited reimbursement coverage, and treatment side effects that affect compliance. In many cases, late-stage diagnoses and regulatory delays further restrict optimal treatment access. Overall, the market is evolving with technology-driven innovations and personalized care strategies, though affordability and accessibility remain critical challenges that need to be addressed.

Facts & Figures

• Rising Global Prevalence of Prostate Cancer: The increasing incidence of prostate cancer, especially among aging men, is a fundamental driver. According to the WHO, prostate cancer is among the top five most diagnosed cancers globally. For instance, as of 2025, global epidemiological projections indicate over 1.8 million new cases annually, with higher detection rates due to awareness campaigns and routine PSA screening.
• Expansion of Targeted and Precision Therapies: Advances in molecular profiling allow tailored therapies, such as PARP inhibitors and BRCA-targeted drugs. This enhances efficacy and reduces side effects. In June 2025, Bayer’s darolutamide was FDA-approved for monotherapy in mCSPC, demonstrating the market’s embrace of precision approaches with better tolerability.
• Innovation in Radioligand Therapy: The market is witnessing a shift to radioligand treatments that target cancer cells precisely, like PSMA-directed therapies. For instance, Novartis’s Pluvicto was approved for pre-chemo mCRPC patients, increasing its eligible base significantly and expanding its role in early-stage disease.
• Technological Advancements in Diagnosis and Monitoring: AI-enabled tools, digital pathology, and improved biomarkers are revolutionizing early detection and patient management. For instance, Multiple AI-based diagnostic tools were showcased in early 2025 oncology conferences, improving PSA interpretation and reducing false positives.

Key Developments

• In June 2025, Bristol Myers Squibb, via its radio pharma subsidiary RayzeBio, entered into a multi-stage deal with Swiss biotech Philochem, paying over $350 million upfront (and potentially $1.35 billion total) for exclusive global rights to OncoACP3, a clinical-stage prostate cancer imaging and therapeutic agent.
• In June 2025, Novartis’s interim analysis from the PSMAddition trial indicates substantial rPFS benefits with Pluvicto plus hormone therapy in metastatic hormone-sensitive prostate cancer, paving the way for expanded indications
• In March 2024, AstraZeneca acquired Fusion Pharmaceuticals for $2?billion, gaining access to their radio conjugate R&D and isotope infrastructure focused on mCRPC. This expands AZ’s radiopharmaceutical pipeline and accelerates clinical development
• In December 2023, Lilly acquired POINT Biopharma, securing radioligand assets like PNT2002 for metastatic castration-resistant prostate cancer. This deal equips Lilly with scalable manufacturing and enhances its position in targeted prostate cancer therapy.

Prostate Cancer Therapeutics Market Segmentation

Based on the type

• Benign Prostatic Hyperplasia
• Prostatic Adenocarcinoma
• Small Cell Carcinoma
• Others

Prostatic adenocarcinoma holds the largest market share in the market, as it is the most common and widely diagnosed type of prostate cancer, especially among aging men. Its high prevalence drives strong demand for targeted therapies and advanced treatment options. In contrast, small cell carcinoma, being a rare and aggressive form, contributes a minimal share due to limited incidence and fewer tailored therapeutic interventions.

Based on the drug class

• Androgen Receptor Inhibitors
• Microtubule Inhibitors
• Gonadotropin-Releasing Hormone (GnRH) Agonist
• Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
• Others

Among the drug classes, androgen receptor inhibitors dominate the market due to their pivotal role in disrupting androgen signaling, which is essential for the growth of most prostate tumors. These inhibitors are widely used in treating both localized and metastatic castration-resistant prostate cancer, offering improved survival rates and better patient outcomes. Their effectiveness, especially in combination therapies, drives their market leadership. Additionally, newer agents in this class are showing promise in earlier stages of the disease. GnRH agonists and antagonists are primarily used in hormonal therapy to suppress testosterone. Microtubule inhibitors, while effective in advanced stages, hold a smaller share due to higher toxicity and limited use in first-line treatment regimens.

Based on the route of administration

• Oral
• Parenteral

In the global prostate cancer therapeutics market, the oral route of administration holds a significant market share due to its convenience, improved patient compliance, and suitability for long-term outpatient treatment. Oral drugs, such as androgen receptor inhibitors, allow patients to manage therapy at home, reducing hospital visits and healthcare costs. This mode is especially favored in elderly populations. Parenteral administration, including intravenous or subcutaneous injections, is typically used for chemotherapy, GnRH agonists/antagonists, or radioligand therapies, offering precise dosing and rapid absorption. While parenteral routes are crucial for advanced or hospital-based treatments, the growing preference for oral therapies continues to shape market trends.

Based on the distribution channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

In the market, hospital pharmacies dominate the distribution channel segment due to the critical nature of cancer care and the administration of high-cost or injectable therapies like chemotherapy and radioligands, which require professional supervision. These pharmacies are integrated within oncology departments, ensuring timely access to medications during inpatient or outpatient treatments. Drug stores & retail pharmacies play a supportive role, particularly for oral therapies like androgen receptor inhibitors, which patients can refill conveniently. Online pharmacies currently have the smallest market share and are witnessing rising traction, especially post-pandemic, offering doorstep delivery and discounts, though their role is still emerging due to prescription regulations and cancer treatment complexity.